First in Human Study of KO-539 in Relapsed or Refractory Acute Myeloid Leukemia


Study Number
84119
Phase
1
Purpose

This first-in-human (FIH) dose escalation will determine the maximum tolerated dose (MTD) of KO-539, a menin-MLL(KMT2A) inhibitor, in patients with refractory or relapsed AML who have failed or are ineligible for any approved standard of care therapies, including HSCT.

Full Title

(KO-MEN-001) A Phase 1 First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO 539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

ClinicalTrials.Gov ID
NCT04067336

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.